US EditionImmunotherapy Enhances Chemotherapy in the Fight Against Stage 3 Colorectal Cancer
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
New research from the Mayo Clinic Comprehensive Cancer Center has shown that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colorectal cancer—and a specific genetic makeup called deficient DNA mismatch repair (dMMR)—was associated with a 50 percent reduction in cancer recurrence and patient death compared with chemotherapy alone. Approximately 15 percent of people diagnosed with colorectal cancer hav…
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
